Authors: Hall, IH Barnes, BJ Ward, ES Wheaton, JR Shaffer, KA Cho, SE Warren, AE

Citation: Ih. Hall et al., Targeting of human Tmolt(4) leukemic type IIIMP dehydrogenase by cyclic imide related derivatives, ARCH PHARM, 334(7), 2001, pp. 229-234

Authors: Hall, IH Barnes, BJ Ward, ES Wheaton, JR Warren, AE Izydore, RA

Citation: Ih. Hall et al., Tmolt(4) leukemic type II isoform of IMP dehydrogenase as a target for 1,2,4-triazolidine-3,5-diones, 1-(1-(3-methylphenyl)ethylidineamino)-4,4-diethyl-3,5-azetidinediones, 3,5-isoxazolidinediones, and 4,4-disubstituted-3,5-pyrazolidinediones, ARCH PHARM, 334(4), 2001, pp. 109-116

Authors: Izydore, RA Zhang, Y Zhou, XM Warren, AE Wheaton, JR Hall, IH

Citation: Ra. Izydore et al., The cytotoxicity of 1-(1-phenylalkylideneamino)-2,4-azetidinediones and their mode of action in human and murine tumor cells, ANTICANC R, 21(1A), 2001, pp. 157-165

Authors: Hall, IH Covington, DW Wheaton, JR Izydore, RA Zhou, XM

Citation: Ih. Hall et al., Cytotoxicity of 2-ethenyl-2,3-dihydrophthalazine-1,4-diones in murine and human tumor cultured cells, PHARMAZIE, 56(2), 2001, pp. 168-174

Authors: Hall, IH Barnes, BJ Ward, ES Wheaton, JR Izydore, RA

Citation: Ih. Hall et al., Specific inhibition of Type II inosine monophosphate dehydrogenase activity of Tmolt(4) T cell human leukaemia cells by 3-methoxy and di-benzohydroxamic acids, maleic hydrazide and malonic acids, J PHARM PHA, 53(5), 2001, pp. 749-755